Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis
AssigneeEli Lilly and Company
InventorMingyang SHAN
Life of this patent
Estimating the term…
Abstract
The present disclosure is generally relates to methods of treating ulcerative colitis. The methods are particularly suitable for treating bowel urgency a specific sub-group of patients with ulcerative colitis and having bowel urgency.
Claims19
A method of treating bowel urgency in a patient having ulcerative colitis, the method comprising:
- obtaining a first sample from the patient;
- analyzing the first sample to detect at least one biomarker selected from C-reactive protein (CRP) and fecal calprotectin (fCLP);
- administering an anti-IL-23p19 antibody to the patient;
- obtaining a second sample from the patient;
- and analyzing the second sample to detect at least one biomarker selected from C-reactive protein (CRP) and fecal calprotectin (fCLP), wherein a change in expression level of the at least one biomarker detected in the second sample from the expression level of the at least one biomarker detected in the first sample indicates a response to the anti-IL-23p19 antibody.
-12. (canceled)
-23. (canceled)
A method of identifying or determining a patient having ulcerative colitis as a candidate patient for receiving an anti-IL-23p19 antibody treatment for bowel urgency, the method comprising:
- obtaining a sample from the patient;
- analyzing the sample for at least one biomarker selected from C-reactive protein (CRP) and fecal calprotectin (fCLP);
- and identifying the patient as a candidate patient for receiving the anti-IL-23p19 antibody treatment for bowel urgency based on the analysis of the at least one biomarker.
-30. (canceled)
A method for identifying risk for bowel urgency in a patient having ulcerative colitis, wherein the method comprises (a) determining an expression level of at least one biomarker selected from C-reactive protein (CRP) and fecal calprotectin (fCLP) in a sample obtained from the patient;
- (b) comparing the determined expression level of the at least one biomarker to a reference expression level of at least one biomarker selected from C-reactive protein (CRP) and fecal calprotectin (fCLP);
- and (c) identifying that the patient is at risk for bowel urgency if the biomarker expression level in the patient is changed as compared to the reference expression level.
-112. (canceled)
A biomarker panel comprising at least one biomarker selected from C-reactive protein (CRP), fecal calprotectin (fCLP), CXCL8, AQP9, IL1B, S100A9, TREM1, MMP12, MMP1, MMP7, TCN1, DUOX2, DUOXA2, SLC6A14, VNN1, ABCA12, REG1B, C4BPA, GUCA2B, OTOP2, AQP8, SLC26A2, ΔDH1C, MMP3, REG3A, DMBT1, REG1P, S100A8, IGKV2D-40, PI3, TNIP3, REG1A, IDO1, NOS2, MMP10, CXCL1, PTGS2, ABCG2, HMGCS2, TMIGD1, GUCA2A, LOC101928405, MS4A12, UGT2A3, TRPM6, NXPE4, SLC16A9, ΔDH1C, PCK1, CDKN2B-AS1, TMEM236, CD177P1, SLC17A4, and ZG16.
Dependencies are inferred from the claim text.